618056-36-3

Upstream product

• 6346-05-0 3-benzyloxy-4-methoxybenzaldehyde 
• 618056-40-9 4-(4-ethyl-6,7-dimethoxy-3-methyliso-chromanyl)-1-methoxy-2-(phenylmethoxy)benzene 
• 621-59-0 isovanillin 
• 618056-34-1 3-(4,5-dimethoxy-2-{[4-methoxy-3-(phenylmethoxy)phenyl] carbonyl}phenyl)pentan-2-one 

Downstream Products

• 75114-20-4 5-Ethyl-1-(3-hydroxy-4-methoxyphenyl)-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepin 

Relevant academic research and scientific papers

Method of increasing neutrophil production using optically-pure (R)-2,3-benzodiazepines

Compounds according to formula I: wherein R1, R2, R3, R4, R5 and n are as defined herein, are administered to increase neutrophil levels in mammels.

Treatment of LTB4-mediated inflammatory disorders with optically-pure (R)-2,3-benzodiazepines

Compounds according to formula I: 1wherein R1, R2, R3, R4, R5 and n are as defined herein, are administered for the treatment of inflammatory disorders mediated by LTB4,

Pharmaceutical composition of 1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine and uses thereof

Pharmaceutical compositions comprise 1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine, or a pharmaceutically acceptable salt thereof. The compositions are used for treating, preventing or delaying the onset of disorders mediated by LTB4 or TXA2.

Modulation of dopamine responses with substituted (S)-2,3-benzodiazepines

Compounds according to formula I: wherein R1, R2, R3, R4, R5 and R6 are as defined herein, and wherein the compound comprises the (S)-enantiomer, administered for modulation of dopamine responses and treatment of dopamine-mediated disorders.

Method of increasing neutrophil production using 2,3-benzodiazepines

Compounds according to formula I: wherein R1, R2, R3, R4, R5 and n are as defined herein, are administered to increase neutrophil levels in mammals.

Treatment of inflammatory disorders with 2,3- benzodiazepines

Compounds according to formula I: 1 wherein R1, R2, R3, R4, R5 and n are as defined herein, are administered for the treatment of inflammatory disorders, particularly inflammatory disorders mediated by LTB4,

Treatment of irritable bowel syndrome and nonulcer dyspepsia with substituted 2,3-benzodiazepines

Compounds according to formula I: are disclosed wherein R1, R2, R3, R4, R5and R6as defined herein, are administered for irritable bowel syndrome and nonulcer dyspepsia.